Cellebrite Reports Q3 Revenue of $126 Million and Net Income of $20.2 Million

Reuters
11/13
<a href="https://laohu8.com/S/CLBT">Cellebrite</a> Reports Q3 Revenue of $126 Million and Net Income of $20.2 Million

Cellebrite DI Ltd. reported third-quarter 2025 results with annual recurring revenue $(ARR)$ up 19% to $439.8 million and revenue increasing 18% to $126.0 million. Net income reached $20.2 million, while non-GAAP net income was $36.9 million. Adjusted EBITDA was $37.7 million, representing a 29.9% adjusted EBITDA margin. For full-year 2025, Cellebrite expects ARR between $460 million and $475 million, reflecting 16% to 20% annual growth, and revenue between $470 million and $475 million, an annual growth of 17% to 18%. Adjusted EBITDA for the year is projected at $124 million to $127 million, with a margin of 26% to 27%. Recent business highlights include the Autumn 2025 Release, featuring advancements in the Digital Investigation Platform and the announcement of the upcoming Guardian Investigate solution, a SaaS-based investigative tool utilizing agentic AI, scheduled for general availability in early 2026. Subscription-based revenue grew by 21% during the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574177-en) on November 12, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10